Microstatins: A new generation of potent cholesterol biosynthesis inhibitors with a reduced interaction potential. Focus on Cerivastatin

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 8, Issue 6, 1998, Pages 392-400

  Sirtori, C R ^a   Bondioli, A ^a   Murakami, T ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerivastatin; Drug interactions; HMG CoA reductase inhibitors; Pharmacokinetics; Statins

Indexed keywords

EID: 0008012229     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Sirtori CR (1990) Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res 22: 555-563
2. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101: 117-125
3. Chen HW (1984) Role of cholesterol metabolism in cell growth. Fed Proc 43: 126-130
4. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, Sirtori CR (1995) Therapy with HMG-CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 117: 189-198
5. Rubinstein A, Weintraub M (1995) Escape phenomenon of low-density lipoprotein chlesterol during lovastatin treatment. Am J Cardiol 76: 184-186.
6. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould-AL, Hesney M, Higgins J, Hurley DP, Langerdorfer A, Nash DT, Pool JL, Schnaper H (1991) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. 1. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia. Arch Intern Med 151: 43-49
7. Neuvonen PJ, Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60: 54-61
8. Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33: 1569-1582
9. Tsujita Y, Kuroda M, Tanzawa K, Kitano N, Endo A (1979) Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32: 307-313
10. Endo A, Tsujita Y, Kuroda M, Tanzawa K (1979) Effects of ML-236B on cholesterol metabolism: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 575: 266-276
11. Sliskovic DR, Roth BD, Bocan TMA (1992) Tissue selectivity of HMG-CoA reductase inhibitors. DN&P 5: 517-533
12. Sirtori CR (1993) Tissue selectivity of hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmacol Ther 60: 431-459
13. Shaw MK, Newton RS, Sliskovic DR, Roth BD, Ferguson E, Krause BR (1990) Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochim Biophys Res Commun 170: 726-734
14. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M (1990) Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045: 115-120
15. Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, Pfitzner J, Porter MC, Schmidt D, Thomas G (1997) Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 135: 119-130
16. Bergstrom JD, Bostedor RG, Rew DJ, Geissler WM, Wright SD, Chao Y-S (1998) Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim Biophys Acta 1389: 213-221.
17. Benoist F, Grand-Perret T (1996) ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. ATVB 16: 1229-1235.
18. Mark M, Muller P, Maier R, Eisele B (1996) Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in Hep G2 cells. J Lipid Res 37: 148-158.
19. Hayashi K, Kurokawa J, Nomura S, Kuga Y, Ohkura Y, Kajiyama G (1993) Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim Biophys Acta 1167: 223-225.
20. Desager JP, Horsmans Y (1996) Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 31: 348-371
21. Transon C, Leemann T, Vogt N, Dayer P (1995) In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 58: 412-417
22. Duggan DR, Vickers S (1990) Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev 22: 333-362
23. Steinke W, Yamashita S, Tabei M, Ahr HI, Beckermann B, Domdey-Bette A, Goller G, Schwarz T, Siefert HM (1996) Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 24: S1217-S1237.
24. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR (1996) Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36: 242-246
25. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35: 261-264
26. Muck W, Ochmann K, Rohde G, Unger S, Kuhlmenn J (1997) Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 53: 469-473
27. Muck W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. J Clin Pharmacol Ther 35: 255-260
28. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (1997) Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic patways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331
29. Muck W (1998) Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs Suppl. 56: 15-23.
30. Corsini A, Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, Fumagalli R (1996) Effect of the new HMG-CoA reductase inhibitor cerivastatin (Bay w 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 33: 55-61
31. Calabresi L, Sirtori CR (1998) Evidence-based medicine criteria applied to hypolipidemic and antihypertensive drug trials: is drug efficacy always the same? Pharmacol Res 37: 339-343
32. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
33. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al (1987) Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317: 1237-1245.
34. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn't. Br Med J 312: 71-72
35. Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. Br Med J 310: 452-454
36. Isles C, Norrie J (1997) Coronary prevention with statins: towards evidence based decisions on the use of lipid lowering drugs. Atheroscler ID Res Alert 2: 89-94
37. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langerdorfer A, Stein EA, Kruyer W, Gotto AM (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279: 1615-1622
38. The Lipid Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357
39. West of Scotland Coronary Prevention Study (1996) Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348: 1339-1342
40. Stein E, Sprecher D, Allenby KS, et al (1997) Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolaemia. J Cardiovasc Pharmacol Ther 2: 7-16
41. Betteridge DJ, International Cerivastatin Study Group. Cerivastatin. Multicentre, double-blind comparison with placebo and simvastatin in primary hypercholesterolaemia. 11th International Symposium on Atherosclerosis (Abstract 1.P.138) 1997, Oct 5-9; Paris. Atherosclerosis 134: 45
42. Insull W, Stein E, Whalen E (1997) Cerivastatin, a new potent HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolaemia (abstract). J Am Coll Cardiol 29, Suppl A: 46A
43. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ (1994). Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 343: 1554-1555
44. Farnier M, Megnien S, Becka M (1997) Comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia. 11th International Symposium on Atherosclerosis (Abstract 2.P.32), 1997 Oct. 5-9; Paris. Atherosclerosis 134: 123
45. Farnier M, Megnien S, Becka M (1997) Long-term extension of the comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia. 11th International Symposium on Atherosclerosis (Abstract 2.P.33), 1997 Oct. 5-9; Paris. Atherosclerosis 134: 123
46. Shannon T, Ripa S, Altavilla M, Kelly F, Larkin S, Shugrue E, Whalen E, Collins S, Higgins K, Heller A. Analysis of an eighteen months long-term extension to as 24-week double-blind dose ranging study of BAY w 6228 in doses of 50 mg, 100 mg, 200 mg and 300 mg once daily compared to placebo and to lovastatin 40 mg once daily in patients with hypercholesterolemia. Study No. BAY w 6228/0124 (D/X91-031). Report No. MMRR 1345
47. Schmage N, Nuremberg C, Becka M (1996) A multinational, multicentre, double-blind, randomized study of BAY w 6228 in doses of 300 μg and 400 μg once daily compared to placebo in patients with primary hypercholesterolaemia. Study No. BAY w 6228/0149. Report No. PH25068, May 13
48. Stein EA (1998) Extending therapy options in treating lipid disorders. A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Drugs Suppl. 56: 25-31
49. Vanhaecke J, Cleemput JV, Van Lierde J, Daenen W, De Geest H (1994) Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 58: 42-45
50. Garnett WR (1995) Interactions with hydroxymethylglutaryl coenzyme A inhibitors. Am J Health Syst Pharm 52: 1639-1645
51. Neuvonen PJ, Kantola T, Kivistö KT (1998). Simvastatin but not pravastatin is very susceptible to interaction with the CYP4503A4 inhibitor itraconazole. Clin Pharmacol Ther 63: 332-341
52. Kantola T, Kivistö KT, Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63: 397-402